Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
A new study by Kaiser Permanente found that mailing human papillomavirus (HPV) self-sampling kits to patients increases cervical cancer screening completion rates. The study also shows that this approach is cost-effective, especially for health systems with a wide range of patient populations.
A groundbreaking study aims to improve genetic services for adolescent and young adult (AYA) cancer survivors by integrating digital tools and chatbot technology. Participants will receive tailored communication, digital education tools, and genetic testing, with the goal of increasing uptake of genetic counseling and testing.
A Virginia Tech oncologist is championing a precise approach to treating acute myeloid leukemia by tracking subtle molecular changes in patients. His work aims to identify signs of potential relapse and tailor treatment for each individual with this rare blood cancer.
A new study discovers a previously unknown long noncoding RNA, EUDAL, that helps oral cancer cells survive chemotherapy by permanently activating the epidermal growth factor receptor. This RNA molecule blocks the cellular tagging system, allowing EGFR to remain active and promote autophagy in cancer cells.
An AI model successfully automates lymph node segmentation and extranodal extension classification from pretreatment CT scans in HPV-associated oropharyngeal carcinoma. Predicted extranodal extension is independently associated with worse oncologic outcomes, highlighting the potential for improved treatment planning.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
A phase III trial suggests that post-operative radiation therapy can reduce cancer recurrence in patients with high-risk disease. Patients who received radiation experienced significantly fewer pelvic recurrences and improved locoregional recurrence-free survival compared to those who did not receive radiation.
A recent study suggests that the rise in early-onset cancer incidence in the US population may not be as significant as initially thought. Much of the increase is attributed to increased diagnostic scrutiny and over-diagnosis, rather than a genuine rise in clinically meaningful cancer cases.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
Dr. Amar Kishan has been recognized for his groundbreaking research on radiation treatments for genitourinary system cancers. He is the recipient of the 2025 Steven A. Leibel Memorial Award, presented by ASTRO and ABR Foundation.
A Harvard Medical School-led research team developed an AI tool called PICTURE that can reliably tell apart glioblastoma and primary central nervous system lymphoma during surgery. The tool distinguishes between the two cancers with near-perfect accuracy, reducing errors in diagnosis and guiding critical treatment decisions.
Researchers have discovered myeloid cells in children's liver tumors that could be activated for treatment. This discovery provides new avenues for immunotherapy in childhood liver cancer.
Researchers at Fox Chase Cancer Center found adaptive radiation therapy can reduce radiation to healthy tissue by 21% while delivering higher doses to tumors. The study offers new hope for patients with previously untreatable cancers.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
A new PSMA-targeting radioligand therapy added to stereotactic body radiotherapy (SBRT) more than doubled progression-free survival in men with recurrent prostate cancer, delaying the start of hormone therapy by up to 24 months. The study found minimal side effects and identified biological markers that may predict treatment benefits.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
Researchers developed a genomic model to tailor radiation doses to individual patients with HPV-positive throat cancer. The study found that higher scores on the Genomic Adjusted Radiation Dose (GARD) model were associated with improved survival outcomes, even when patients received the same radiation dose.
A new study suggests that low-dose aspirin can prevent cancer in older adults based on individual characteristics. The analysis found varying treatment effects among participants, highlighting the need for personalized approaches to cancer prevention.
Researchers at UC Irvine have developed a novel immunotherapeutic approach that targets cancer-associated glycans to trigger tumor cell death. The therapy, called GlyTR, has shown safety and effectiveness in models of various cancers, including leukemia, and is expected to pave the way for targeted T-cell therapy to solid tumors.
Scientists introduce a new way to control when drugs are active or inactive in the body, potentially developing safer medicines. The technology was applied to create improved molecular sensors, including a rapid coronavirus sensor that responds about 70 times faster than previous protein-based tests.
Scientists develop novel experimental screening method to identify highly selective peptides with high therapeutic potential, enabling precise recognition of proteins involved in cancer and diabetes. The technique uses biologically- and chemically-modified bacteriophages to screen up to 1 billion peptides simultaneously.
A new robot-assisted bronchoscope has been shown to diagnose tiny lung tumors in hard-to-reach areas with over 84% success rate, more than three times higher than traditional methods. The technology enables accurate diagnosis in patients where conventional bronchoscopy offers no viable option.
A study has identified KIMA, a genomic signature associated with a poor treatment response in HR+/HER2- breast cancer patients. The signature, composed of nine genes, can predict disease progression and overall survival, enabling personalized therapy selection.
Duke University researchers discovered that inhibiting an enzyme involved in iron regulation makes cancer cells vulnerable to cell death. By targeting STK17B kinase, they reactivated ferroptosis and increased the effectiveness of conventional therapies against multiple myeloma.
Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.
A new study published in Diabetes, Obesity and Metabolism found that weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes. The study analyzed data from over 180,000 people and found a significant reduction in cancer incidence ...
A 71-year-old man was diagnosed with advanced colorectal cancer after suffering from multiple unexplained strokes and blood clots. The cancer remained undetected until widespread clot complications appeared, highlighting the need for comprehensive oncologic evaluation in patients with unexplained hypercoagulable states.
A study by University of Florida researchers found that 93% of new cancer patients are exposed to at least one type of misinformation about cancer treatments. The most common sources were second-hand information from friends, family, social media, and news outlets. The study suggests that clinicians should assume their patients have be...
Global cancer cases and deaths are projected to increase substantially from 2024 to 2050, with a focus on low- and middle-income countries. The study highlights the need for urgent action and targeted funding to address the growing burden of cancer.
Researchers identified a cellular mechanism that alters the gut microbiome in a way that promotes cancer. Long-chain fatty acids serve as food for certain bacteria, such as Desulfovibrio fairfieldensis, which multiply and displace other microbes.
The loss of Trp53 leads to more aggressive tumor growth and weaker immune responses in ovarian cancer. Researchers developed a mouse model that mimics human HGSC, showing how the disease progresses and evades the immune system.
A new study found that fat distribution appears to influence cancer risk, but the relationship varies by cancer type. The study used Mendelian randomization to investigate the role of adiposity distribution in 12 obesity-related cancers.
Dr. Eggener brings extensive expertise in prostate and testicular cancer detection, diagnosis, and treatment to UCLA Health. He aims to improve prostate cancer detection and treatment through research.
A recent analysis reveals a modest decline in new and additional opioid prescriptions for patients with cancer from 2016 to 2020. For patients with metastatic cancer, prescribing remained stable for those reporting any pain but declined steeply for those reporting no pain.
Researchers at St. Jude Children's Research Hospital have implicated lipids in the initiation of LC3-associated phagocytosis (LAP), a specialized process for degrading dead cells and microbes. This finding opens new avenues for exploring therapeutic strategies to modulate LAP in diseases such as cancer and autoimmune disorders.
Researchers developed an engineered strain of gut-homing bacteria that induces mature tertiary lymphoid structures, associated with improved survival and stronger treatment responses. The therapy also restored healthy gut microbiota and showed excellent biocompatibility.
Researchers discovered PRMT5 regulates ACSL4 methylation, which promotes ferroptosis in renal cell carcinoma. Inhibiting PRMT5 increases ferroptosis and enhances immunotherapeutic treatment efficacy.
Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.
A large-scale population study found that oxaliplatin benefits only younger stage III patients, with no added survival benefit for those over 70. The study suggests using an age threshold to make evidence-based choices about chemotherapy.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
The NRG Oncology PREDICT-RT study has completed patient accrual, evaluating intensified and de-intensified concurrent radiation regimens for high-risk prostate cancer patients. The study aims to improve quality of life and outcomes by tailoring treatments based on genomic risk scores.
Researchers discovered that blocking two key proteins, Ref-1 and PRDX1, significantly shrunk tumors and increased cancer cell death. The approach also affected the tumor's surrounding environment, highlighting its effectiveness in disrupting the tumor's support system.
A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.
Researchers have identified a secreted form of a protein called Clever-1 that systemically suppresses T cells essential for fighting cancer. The investigational anti-Clever-1 antibody, bexmarilimab, directly inhibits the release of sClever-1, potentially predicting treatment resistance and paving the way for new combination treatments.
A Lund University AI model analyzed mammograms to identify breast cancer patients at high risk of armpit metastasis, suggesting that 41.7% of axillary surgeries could be avoided. The study's findings have the potential to revolutionize breast cancer treatment by enabling more personalized care and reducing unnecessary surgeries.
Researchers developed a fusion protein that blocks the 'do not attack' signal and selectively activates tumor-fighting immune cells. The molecule, combining an IL-2 variant with a PD-1 antibody, induces a multifaceted anti-tumoral T cell response in human lung cancer patients.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
This study analyzed adverse events following HPV vaccination in male recipients of Gardasil 9 and Gardasil. The results showed that most AEFI reports occurred within 30 days post-vaccination, with a lower cumulative incidence for Gardasil 9, suggesting a potentially more favourable safety profile.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
A cohort study suggests nicotinamide reduces skin cancer risk, with greatest effect seen after initial skin cancer diagnosis, indicating potential chemopreventive properties of the vitamin B3 derivative
A growing body of research links environmental pollutants to worsened health and shorter life spans in childhood cancer survivors. The study found that only 25% of pediatric oncology providers felt comfortable discussing environmental pollutant impacts with patients.
A novel method combining biological experiments and information science techniques reveals cancer cells' preference for aerobic glycolysis despite sufficient oxygen availability. This research provides a powerful tool for identifying metabolic vulnerabilities in cancer cells, which could lead to more effective treatments.
Researchers from the Stowers Institute for Medical Research have identified a common process that powers the creation of protein formations that assemble like a 3D puzzle, triggering inflammation and cell death. This 'Catch-22' mechanism may be one of the fundamental reasons why we age.
A $1.7M Department of Defense grant funds the Convergent Science Virtual Cancer Center, strengthening expertise in cancer risks faced by military personnel and their families. The center provides personalized mentorship, immersive workshops, and non-traditional educational opportunities to improve patient outcomes across various cancers.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
Research has shown that lymph nodes provide the right environment for stem-like T cells to survive, multiply, and produce killer cells. Preserving lymph nodes could strengthen immune responses and increase the effectiveness of immunotherapy. The study's findings have important implications for cancer therapy.
Researchers have found that a unique surgical technique combining radiation with silicone oil shows unexpectedly low rates of cancer metastasis and death in patients with uveal melanoma. Over four years, more than 80% of patients remained free of metastatic disease.
Middle-aged adults diagnosed with acute cystitis are at higher risk of urogenital cancer, particularly prostate and bladder cancers. The risks persist for several years after infection, especially within 3 months of symptoms, with men being more likely to develop the condition.